GoodRx adds former Genentech CEO Ian Clark to board, creates Innovation Committee

GoodRx Holdings, Inc.

Ian T. Clark elected Class III director effective July 8, 2024; fills vacancy from Stephen LeSieur's March resignation.
Clark chairs newly created Innovation Committee; also joins Nominating and Corporate Governance Committee.
Granted initial RSU award worth $420,000 and pro-rated annual award of $209,836 under director compensation plan.
Board combined Audit and Compliance committees into a single Audit and Risk Committee.
Clark brings 35+ years pharma/healthcare experience; board deems him independent under Nasdaq rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ian T. Clark

Class III Director

GDRX · GoodRx Holdings, Inc.

Effective: 2024-07-08
Filed: July 10, 2024, 7:59 PM ET

On July 8, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ian T. Clark as a Class III director, effective immediately, to fill the vacancy on the Board created by the resignation of Stephen LeSieur.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ian T. Clark was elected as Class III Director at GoodRx Holdings, Inc..

Action: elected
Role: Class III Director

Exact text from the filing

On July 8, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ian T. Clark as a Class III director, effective immediately, to fill the vacancy on the Board created by the resignation of Stephen LeSieur.

View on SEC.gov

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-24-000133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.